Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 5 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Neoplasms 3 Lung Neoplasms 3 Solid Tumors 1 Rectal Neoplasms 1 Pleural Effusion 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Insulin-Like Growth Factor I, Resistance To 1 Fallopian Tube Neoplasms 1 Advanced Solid Tumors 1 Adenocarcinoma 1

Interventions

Injections 27 Carboplatin 18 Docetaxel 14 pembrolizumab 13 Paclitaxel 12 Bevacizumab 10 durvalumab 8 Nivolumab 8 Cisplatin 8 Fluorouracil 7 Pemetrexed 6 Oxaliplatin 6 Leucovorin 6 trifluridine tipiracil drug combination 5 toripalimab 5 tislelizumab 5 linifanib 5 Capecitabine 5 zimberelimab 4 talazoparib 4 olaparib 4 fludarabine 4 Panobinostat 4 Itraconazole 4 Irinotecan 4 Gemcitabine 4 Everolimus 4 tremelimumab 3 sotorasib 3 sintilimab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Solid Tumors × dalotuzumab × Clear all

NCT00635778 2018-10-09

MK-0646-002

Merck Sharp & Dohme LLC

Phase 1 Completed

50 enrolled 32 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡